Survey Results on Industry Practices and Challenges in Subgroup Analysis in Clinical Trials

Statistics in Biopharmaceutical Research

Volumn 7, Issue 4, 2015, Pages 272-282

  Mayer, Cristiana ^a   Lipkovich, Ilya ^a   Dmitrienko, Alex ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b IQVIA   (United States)

Author keywords

Clinical trials; QSPI; Statistical methodologies; Subgroup analysis and identification; Survey

Indexed keywords

CLINICAL TRIAL; HUMAN; SAMPLE SIZE;

EID: 84950315593     PISSN: None     EISSN: 19466315     Source Type: Journal    
DOI: 10.1080/19466315.2015.1062044     Document Type: Article

References (20)

1. S.F.Assmann,, S.J.Pocock,, L.E.Enos,, and L.E.Kasten, (2000), “Subgroup Analysis and Other (mis)uses of Baseline Data Inclinical Trials,” Lancet, 355, 1064–1069.
2. L.Breiman,, J.H.Friedman,, R.A.Olshen,, and C.J.Stone, (1984), Classification and Regression Trees, Belmont, CA: Wadsworth.
3. S.T.Brookes,, E.Whitley,, T.J.Peters,, P.A.Mulheran,, M.Egger,, and S.G.Davey, (2001), “Subgroup Analyses in Randomized Controlled Trials: Quantifying the Risks of False-Positives and False-Negatives,” Health Technology Assessment, 5, 1–56.
4. T.Cai,, L.Tian,, P.Wong,, and L.J.Wei, (2011), “Analysis of Randomized Comparative Clinical Trial Data for Personalized Treatment Selections,” Biostatistics, 12, 270–282.
5. G.Chen,, H.Zhong,, A.Belousov, and D.Viswanath, (2015), “PRIM Approach to Predictive-Signature Development for Patient Stratification,” Statistics in Medicine, 34, 317–342.
6. European Medicines Agency (2013), “Guideline on the Investigation of Subgroups in Confirmatory Clinical Trials,“ (23 January 2013), available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/02/WC500160523.pdf.
7. Executive Office of the President (2014), “Big Data: Seizing Opportunities, Preserving Values,” available at http://www.whitehouse.gov/issues/technology/big-data-review. Accessed February 2015.
8. J.C.Foster,, J.M.Taylor,, and S.J.Ruberg, (2011), “Subgroup Identification From Randomized Clinical Trial Data,” Statistics in Medicine, 30, 2867–2880.
9. B.Freidlin,, W.Jiang,, and R.Simon, (2010), “Adaptive Signature Design: The Cross-Validated Adaptive Signature Design,” Clinical Cancer Research, 16, 691–698.
10. ICH (1998), International Conference on Harmonisation of Technical Requirements For Registration of Pharmaceuticals for Human Use: ICH Harmonised Tripartite Guideline Statistical Principles for Clinical Trials E9 (February 1998), available at http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed January 2015.
11. I.Lipkovich,, and A.Dmitrienko, (2014), “Strategies for Identifying Predictive Biomarkers and Subgroups With Enhanced Treatment Effect in Clinical Trials Using SIDES,” Journal of Biopharmaceutical Statistics, 24, 130–153.
12. I.Lipkovich,, A.Dmitrienko,, J.Denne,, and G.Enas, (2011), “Subgroup Identification based on Differential Effect Search (SIDES)—A Recursive Partitioning Method for Establishing Response to Treatment in Subject Subpopulations,” Statistics in Medicine, 30, 2601–2621.
13. W.-Y.Loh,, X.He,, and M.Man, (2015), “A Regression Tree Approach to Identifying Subgroups With Differential Treatment EffectsStatistics in Medicine, 34, 1818–1833.
14. P.M.Rothwell, (2005), “Subgroup Analysis in Randomized Controlled Trials: Importance, Indications, and Interpretation,” Lancet, 365, 176–186.
15. W.Raghupathi,, and V.Raghupathi, (2014), “Big Data Analytics in Healthcare: Promise and Potential,” Health Information Science and Systems, 2(3), 1–10.
16. X.Su,, C.L.Tsai,, H.Wang,, D.M.Nickerson,, and B.Li, (2009), “Subgroup Analysis via Recursive Partitioning,” Journal of Machine Learning Research, 10, 141–158.
17. X.Sun,, M.Briel,, S.D.Walter,, and G.H.Guyatt, (2010), “Is a Subgroup Effect Believable? Updating Criteria to Evaluate the Credibility of Subgroup Analyses,” British Medical Journal, 340, 850–854.
18. R.Varadhan,, J.B.Segal,, C.M.Boyd,, A.W.Wu,, and C.O.Weiss, (2013), “A Framework for the Analysis of Heterogeneity of Treatment Effect in Patient-Centered Outcomes Research,” Journal of Clinical Epidemiology, 66, 818–825.
19. S.Yusuf,, J.Wittes,, J.Probstfield,, and H.A.Tyroler, (1991), “Analysis and Interpretation of Treatment Effects in Subgroups of Patients in Randomized Clinical Trials,” Journal of the American Medical Association, 266, 93–98.
20. Y.Zhao,, D.Zheng,, A.J.Rush,, and M.R.Kosorok, (2012), “Estimating Individualized Treatment Rules Using Outcome Weighted Learning,” Journal of the American Statistical Association, 107, 1106–1118.